^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA2 underexpression

    i
    Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
    Entrez ID:
    675
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Fatty acid desaturase 1 (FADS1) is a cancer marker for patient survival and a potential novel target for precision cancer treatment. (PubMed, Front Oncol)
    Lastly, single nucleotide polymorphisms (SNPs) which are well-established expression quantitative trait loci (eQTLs) for FADS1 in normal human tissues are also significantly correlated with FADS1 expression in tumors of multiple tissue types, potentially serving as a marker to stratify cancer patients with high/low FADS1 expression in their tumor tissue. Our study suggests that FADS1 plays multiple roles in cancer biology and is potentially a novel target for precision cancer treatment.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 expression • BRCA2 expression • BRCA2 underexpression
    over2years
    Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma. (PubMed, Arch Pathol Lab Med)
    B7-H3 on SCs was negatively correlated with CD45RO T cells, whereas PD-L1 on SCs was related to high densities of CD3, CD4, CD8, CD45RO, and Foxp3 T cells and B7-H4 was more common in tumors with a low CD8 status. We identified B7 family checkpoint molecules as potentially prognostic indicators, combined with different DDR molecular statuses and complex immune infiltrates, in PDAC.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • TP53 wild-type • BRCA1 expression • BRCA2 expression • BRCA2 underexpression
    over2years
    Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. (PubMed, J Pathol Clin Res)
    Targeting Siglec-15 may be a novel therapeutic option for patients who are unresponsive to anti-PD-1 therapy. Future studies are needed to validate the prognostic significance of Siglec-15 and to investigate its regulatory mechanisms in this disease.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    PD-L1 negative • BRCA1 expression • BRCA1 underexpression • BRCA2 overexpression • BRCA2 expression • BRCA2 underexpression • SIGLEC15 expression